Borrmann Type 3 Gastric Cancer And Its Survival Rates

Gastric cancer can be classified into four types according to the Borrmann classification, which is based on the macroscopic appearance of the tumor. Borrmann Type 3 refers to ulcerative tumors with elevated margins, and many patients and physicians wonder how this classification affects overall prognosis. However, the curability and survival rates of gastric cancer are not determined solely by the Borrmann classification.

The primary factors influencing treatment outcomes and long-term survival include the stage of gastric cancer at diagnosis, histological type, tumor differentiation, and the treatment approach used. Borrmann Type 3 itself is not a decisive factor in predicting survival rates. Instead, the most critical determinant of prognosis is the pathological staging of the cancer.

For instance, patients diagnosed with Stage I gastric cancer have a 5-year survival rate of over 90% if treated early with surgical resection. In Stage II, the 5-year survival rate ranges between 60% and 70%. As the disease progresses to Stage III, the survival rate drops significantly, falling between 30% and 40%. In Stage IV, which indicates advanced or metastatic gastric cancer, the 5-year survival rate is only around 2% to 5%.

This highlights the importance of early detection and timely intervention in gastric cancer management. When gastric cancer is identified at an early stage, complete surgical removal of the tumor offers the best chance for long-term survival. However, once the cancer reaches an advanced stage, treatment options such as chemotherapy, targeted therapy, and immunotherapy may offer limited benefits in terms of extending survival or improving quality of life.

In conclusion, while Borrmann Type 3 gastric cancer has its distinct morphological features, the overall prognosis depends heavily on the cancer stage and the effectiveness of timely treatment. Regular screening and awareness of early symptoms are crucial for improving outcomes in gastric cancer patients.